Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Meera Mohan MD

Meera Mohan MD profile photo picture

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center
Member of the Center for Immunology

View Curriculum Vitae

Publications (8)

  • Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. (Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R) Blood Cancer J 2024 Mar 05;14(1):35 PMID: 38443345 PMCID: PMC10914756 SCOPUS ID: 2-s2.0-85186867281 03/06/2024       42 Citations
  • Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. (Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M) Blood Cancer J 2024 Mar 05;14(1):36 PMID: 38443341 PMCID: PMC10914796 SCOPUS ID: 2-s2.0-85186936720 03/06/2024       7 Citations
  • Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. (Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR) Blood Cancer J 2024 Jan 25;14(1):20 PMID: 38272897 PMCID: PMC10810902 SCOPUS ID: 2-s2.0-85183048072 01/26/2024       13 Citations
  • Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M) Bone Marrow Transplant 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024       3 Citations
  • Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. (Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A) Blood Cancer J 2023 Nov 27;13(1):172 PMID: 38012151 PMCID: PMC10682473 SCOPUS ID: 2-s2.0-85178137180 11/28/2023       15 Citations
  • Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. (Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R) Leuk Res 2023 Aug;131:107324 PMID: 37285641 SCOPUS ID: 2-s2.0-85161348747 06/08/2023       5 Citations
  • Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. (Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD Jr, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M) Cancer 2023 Aug 15;129(16):2491-2498 PMID: 37282609 SCOPUS ID: 2-s2.0-85161608085 06/07/2023       6 Citations
  • Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. (Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M) JAMA Netw Open 2022 Oct 03;5(10):e2238961 PMID: 36306135 PMCID: PMC9617177 SCOPUS ID: 2-s2.0-85141003728 10/29/2022       28 Citations
    • Last update: 06/04/2024